Dyslipidemia in the Elderly: Should it Be Treated?
- 8 January 2010
- journal article
- review article
- Published by Wiley in Clinical Cardiology
- Vol. 33 (1) , 4-9
Abstract
Elderly or older adults constitute a rapidly growing segment of the United States population, thus resulting in an increase in morbidity and mortality related to cardiovascular disease—an increase that is reaching epidemic proportions. Dyslipidemia is a well established risk factor for cardiovascular disease and is estimated to account for more than half of the global cases of coronary artery disease. Despite the increased prevalence of dyslipidemia in the older adult population, controversy persists regarding the benefits of treatment in this group. Epidemiologic studies have shown that dyslipidemia is often underdiagnosed and under treated in this population probably as a result of a paucity of evidence regarding the impact of treatment in delaying the progression of atherosclerotic disease, concerns involving increased likelihood of adverse events or drug interactions, or doubts regarding the cost effectiveness of lipid‐lowering therapy in older adults. In conclusion, despite the proven efficacy of lipid‐lowering therapy in decreasing cardiovascular morbidity and mortality, these therapies have been underutilized in older patients. CopyrightKeywords
This publication has 40 references indexed in Scilit:
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and MethodsThe American Journal of Cardiology, 2007
- Effects of High-Dose Atorvastatin in Patients ≥65 Years of Age With Acute Coronary Syndrome (from the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering [MIRACL] Study)The American Journal of Cardiology, 2007
- Analysis of Efficacy and Safety in Patients Aged 65–75 Years at RandomizationDiabetes Care, 2006
- Heart Disease and Stroke Statistics—2006 UpdateCirculation, 2006
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Physiological predictors of increasing total and central adiposity in aging men and womenArchives of internal medicine (1960), 1995
- Mechanisms of fatty acid-induced inhibition of glucose uptake.Journal of Clinical Investigation, 1994
- Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)The American Journal of Cardiology, 1993